Intensification Of Antiretroviral Therapy With Raltegravir Or Addition Of Hyperimmune Bovine Colostrum In HIV-infected Patients With Suboptimal CD4+ T-cell Response: A Randomized Controlled Trial

この研究の注釈:

Supplementation of 1,200mg colostrum (40% immunoglobulins) daily for 24 weeks in HIV infected persons on stable antiretroviral therapy (known to decrease CD4+ lymphocytes) failed to improve the suppressed lymphocytes relative to control. Serum HIV-RNA was also not affected by therapy.


ColoPlus, A New Product Based On Bovine Colostrum, Alleviates HIV-associated Diarrhoea

この研究の注釈:

In HIV-infected persons with associated diarrhea, a colostrum containing porridge known as ColoPlus (32% colostrum, where each 50g pack contained 2-4g immunoglobulins and is taken twice daily) for four weeks was able to greatly reduce daily bowel movements from 7 down to 1.6, the benefit lasting for an additional two weeks after supplement cessation.

It was noted that CD4+ lymphocytes increased in all persons, to a larger degree in those with less than 200 cells per microliter (experiencing a 94-110% increase) and that fatigue associated with HIV was reduced 81%.


Effect Of A Mixture Of Micronutrients, But Not Of Bovine Colostrum Concentrate, On Immune Function Parameters In Healthy Volunteers: A Randomized Placebo-controlled Study

この研究の注釈:

Supplementation of colostrum (1,200mg, conferring 500mg immunoglobulins) failed to appreciably influence various immune parameters and DTH responsiveness relative to placebo.


Effect Of Bovine Colostrum-based Food Supplement In The Treatment Of HIV-associated Diarrhea In Northern Uganda: A Randomized Controlled Trial

この研究の注釈:

50g of a colostrum containing porridge (twice daily) for four weeks to persons with HIV-associated diarrhea for four weeks (and followed up for an additional five) significantly reduced stool frequency 79% (58% in controls given standard anti-diarrhea therapy) and increased CD4+ lymphocytes 14% despite a 12% decrease in control. Fatigue was reported to be reduced by 85% relative to baseline, greater than the 43% reduction seen with placebo.